Invesco Pharmaceuticals ETF
PJP
79 hedge funds and large institutions have $58.4M invested in Invesco Pharmaceuticals ETF in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 21 reducing their positions, and 15 closing their positions.
1.55% more ownership
Funds ownership: 17.35% → 18.9% (+1.5%)
5% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 21
5% less capital invested
Capital invested by funds: $61.3M → $58.4M (-$2.97M)
10% less funds holding
Funds holding: 88 → 79 (-9)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.39M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$634K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$231K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$215K |
| 5 |
MPCG
Matrix Private Capital Group
New York
|
+$166K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
USCWA
U.S. Capital Wealth Advisors
Austin,
Texas
|
-$1.84M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.29M |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
-$548K |
| 4 |
LPL Financial
San Diego,
California
|
-$540K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$281K |
PJP Hedge Fund Activity: Q2 2022 in Review
79 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q2 2022, worth a combined $58.4M — down 4.8% from $61.3M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PJP and 6 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 20 added.
The largest buyer was Morgan Stanley, adding an estimated $6.39M. The largest seller was U.S. Capital Wealth Advisors, exiting entirely with an estimated $1.84M sold.
- 79 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q2 2022, down from 88 in Q1 2022.
- Funds reported $58.4M of Invesco Pharmaceuticals ETF stock for Q2 2022, down 4.8% quarter-over-quarter.
- 6 funds opened new Invesco Pharmaceuticals ETF positions in Q2 2022 and 15 closed out, a net change of -9 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q2 2022 was Morgan Stanley, an estimated $6.39M added.
- The largest Invesco Pharmaceuticals ETF seller in Q2 2022 was U.S. Capital Wealth Advisors, an estimated $1.84M sold.
Based on aggregated 13F filings for Q2 2022.